Global Infertility Treatment Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2032

Infertility Treatment Market Size

• The global infertility treatment market size was valued at USD 1.89 billion in 2024 and is expected to reach USD 3.50 billion by 2032, at a CAGR of 8.03% during the forecast period
• This growth is driven by factors such as the declining fertility rates, lifestyle factors, advancements in art

Infertility Treatment Market Analysis

• From the name itself, it is clear that infertility treatment is the treatment options available to treat an individual suffering from infertility. Infertility is a medical condition of an individual’s inability to reproduce owing to the dearth of fertile semen
• Infertility occurs due to various reasons however this doesn’t mean that it cannot be treated or there are any dearth of alternatives
• North America is expected to dominate the infertility treatments market due to high infertility rates and advanced healthcare infrastructure
• Asia-Pacific is expected to be the fastest growing region in the infertility treatment market during the forecast period due to affordable and high-quality fertility treatments
• Assisted Reproductive Technology (ART) segment is expected to dominate the market with a market share of 83.8% due to its continuous improvements in ART techniques

Report Scope and Infertility Treatment Market Segmentation

Infertility Treatment Market Trends

“Technological Advancements in Assisted Reproductive Technologies (ART)”

• The adoption of Artificial Intelligence (AI) and robotic systems in ART procedures, such as robotic cryopreservation and electronic witnessing systems, has enhanced precision and efficiency in fertility treatments
• Time-lapse imaging systems are increasingly used in IVF procedures to monitor embryo development, improving embryo selection and increasing pregnancy rates.
• The rise of at-home fertility testing kits and telemedicine consultations has made infertility treatments more accessible, especially during the COVID-19 pandemic
• Advancements in genetic screening and personalized treatment plans are leading to higher success rates in ART procedures

Infertility Treatment Market Dynamics

Driver

“Declining Global Fertility Rates”

• Global fertility rates have declined, leading to increased demand for infertility treatments
• Factors such as delayed marriages and age-related infertility are contributing to the rising need for assisted reproductive technologies
• Growing awareness about infertility issues and available treatments is encouraging individuals to seek medical assistance
• Countries are implementing policies and subsidies to make infertility treatments more accessible and affordable

Opportunity

“Expansion in Emerging Markets”

• Countries such as India, China, and Brazil are investing in healthcare infrastructure, creating opportunities for infertility treatment providers
• Emerging markets are becoming hubs for medical tourism due to affordable and high-quality fertility treatments
• Increasing insurance coverage for infertility treatments in emerging economies is making these services more accessible
• The expanding middle class in emerging markets is leading to higher disposable incomes, increasing the demand for fertility services

Restraint/Challenge

“High Costs and Ethical Concerns”

• The high cost of assisted reproductive technologies, such as IVF, can be prohibitive for many individuals, especially in developed markets where insurance coverage is limited
• In many regions, infertility treatments are not fully covered by insurance, leading to out-of-pocket expenses for patients
• Procedures such as Pre-Implantation Genetic Testing (PGT) raise ethical concerns regarding genetic selection and the potential for 'designer babies'

• Inconsistent regulations and policies across countries can affect the accessibility and quality of infertility treatments

Infertility Treatment Market Scope

The market is segmented on the basis of sex, diagnosis, drugs, and techniques.

In 2025, the assisted reproductive technology (ART) is projected to dominate the market with a largest share in techniques segment

The assisted reproductive technology (ART) segment is expected to dominate the Infertility Treatment market with the largest share of 83.7% in 2025 due to Continuous improvements in ART techniques, such as embryo culture media and genetic screening, have enhanced the success rates of IVF, making it a preferred choice for many couples.

The clomiphene citrate is expected to account for the largest share during the forecast period in drugs market

In 2025, the clomiphene citrate segment is expected to dominate the market with the largest market share due to most commonly prescribed first-line oral fertility drug, especially for women with ovulatory dysfunction. Its effectiveness and low cost contribute to its leading market share according to multiple clinical and market analyses including.

Infertility Treatment Market Regional Analysis

“North America Holds the Largest Share in the Infertility Treatment Market”

• North America held the largest share of the global infertility treatment market, driven by high infertility rates and advanced healthcare infrastructure
• The U.S. boasts high success rates for Assisted Reproductive Technologies (ART), with IVF success rates
• Significant government initiatives, including subsidizing up to 70% of IVF costs, have enhanced accessibility to fertility treatments  
• The region leads in adopting advanced ART procedures, contributing to its market dominance
• Favorable reimbursement schemes and high patient awareness further bolster the market's growth in North America

“Asia-Pacific is Projected to Register the Highest CAGR in the Infertility Treatment Market”

• APAC is experiencing the fastest growth in the infertility treatment market, with countries such as China, India, and Japan leading the way
• Infertility affects 15 to 20 million couples in India alone, contributing to the region's growing demand for fertility treatments
• Countries such as India and Thailand are becoming popular destinations for medical tourism due to affordable and high-quality fertility treatments
• India's implementation of the Assisted Reproductive Technology (Regulation) Act and the Surrogacy (Regulation) Act in 2022 has regulated and promoted fertility treatments  
• The adoption of advanced medical devices and healthcare services is accelerating the growth of the infertility treatment market in APAC

Infertility Treatment Market Share

The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.

The Major Market Leaders Operating in the Market Are:

• The Cooper Companies Inc. (U.S.)
• Cook (U.S.)
• Vitrolife (Sweden)
• Thermo Fisher Scientific, Inc. (U.S.)
• Esco Micro Pte. Ltd. (Singapore)
• Genea Biomedx (Australia)
• IVFtech ApS (Denmark)
• FUJIFILM Irvine Scientific (U.S.)
• The Baker Company, Inc. (U.S.)
• Kitazato Corporation (Japan)
• Rocket Medical plc (U.K.)
• IHMedical A/S (Denmark)
• Hamilton Thorne Ltd. (U.S.)
• Carl Zeiss AG (Germany)
• MedGyn Products, Inc. (U.S.)
• DxNow, Inc. (U.S.)
• Nidacon International AB (Sweden)
• Gynotec B.V. (Netherlands)

• SAR Healthline Pvt. Ltd. (India)InVitroCare Inc. (U.S.)

Latest Developments in Global Infertility Treatment Market

• In May 2024, a potential male birth control injection, targeting the STK33 protein to render sperm immobile, has shown promise in mice. Injected twice daily for 21 days, male mice were temporarily infertile, with only one out of 13 mice impregnating a female after treatment. Infertility reversed three weeks after cessation of treatment, with no recorded side effects. Researchers aim to test an oral version in primates. While effective, experts suggest other approaches, such as the NES/T gel containing synthetic hormones, may offer faster results in humans
• In May 2024, a recent study conducted by Rutgers Health experts revealed that infertility treatment patients face an increased risk of post-delivery hospitalization for heart disease compared to spontaneously conceived patients. Analyzing over 31 million hospital records, researchers found that infertility patients were twice as likely to be hospitalized for heart disease and hypertension in the year following delivery. The study emphasizes the importance of early postpartum checkups, particularly for patients who undergo infertility treatment to conceive
• In February 2024, Lupin Limited launched Ganirelix Acetate Injection, 250 mcg/0.5 mL, single-dose prefilled syringe in the U.S. Approved by the FDA, it is a generic equivalent to Organon USA LLC's Ganirelix Acetate Injection. The treatment aims to inhibit premature LH surges in women undergoing controlled ovarian hyperstimulation
• In June 2023, Quantum Health partnered with Progyny, Inc. to introduce Quantum Health’s Comprehensive Care Solutions platform for family building and fertility solutions
• In April 2023, Cryoport, Inc. signed 3 years supply chain agreement with the Boston IVF to support the reproductive material shipment across the U.S.     

SKU-9906